On September 19, 2025, the U.S. Food and Drug Administration (FDA) approved a new administration method for Keytruda (pembrolizumab). Under the new approval, Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) can now be given by subcutaneous injection, commonly known as a shot, [...]
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]
On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). This approval was based on the [...]
Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous [...]